Kenneth Frazier

Template:Infobox person

Kenneth Carleton Frazier (born December 17, 1954) is an American business executive and lawyer who served as chief executive officer (CEO) of Merck & Co. (known as MSD outside North America) from 2011 to 2021 and currently serves as the company's executive chairman. Frazier is the first African American to lead a major pharmaceutical company, breaking a significant barrier in one of America's most important industries.

Frazier's path to the CEO's office was unusual. A lawyer by training who joined Merck as general counsel, he rose to prominence by successfully defending the company against thousands of lawsuits related to the anti-inflammatory drug Vioxx, potentially saving Merck billions of dollars. His legal acumen, combined with his subsequent success in leading Merck's pharmaceutical operations, demonstrated leadership capabilities that led to his selection as CEO.

Beyond his business achievements, Frazier has emerged as one of America's most prominent voices on racial justice and corporate responsibility. He was the first CEO to resign from President Donald Trump's American Manufacturing Council in August 2017, citing Trump's response to the white supremacist violence in Charlottesville, Virginia. His CNBC interview following the murder of George Floyd in 2020, in which he spoke movingly about what it means to be Black in America, was widely viewed and quoted.

Frazier was named to Time's list of the 100 most influential people in the world in both 2018 and 2021. In 2018, he was elected to the American Philosophical Society, one of America's most prestigious learned societies.

Early life and education

Childhood in North Philadelphia

Kenneth Carleton Frazier was born on December 17, 1954, in North Philadelphia, a predominantly African American neighborhood in Philadelphia, Pennsylvania. His father, Otis Frazier, worked as a janitor—a humble occupation that nonetheless provided stability for the family.

Frazier's childhood was marked by tragedy when his mother died when he was just twelve years old. This early loss shaped his character and worldview, teaching him resilience and the importance of perseverance in the face of adversity.

Growing up in North Philadelphia during the Civil Rights Movement, Frazier was exposed to both the challenges facing African Americans and the possibilities opened up by the struggle for equality. Thurgood Marshall, the first African American Supreme Court justice and legendary civil rights lawyer, became one of his heroes—a fitting inspiration for someone who would later combine legal and business careers.

Education

Frazier attended Julia R. Masterman School and Northeast High School in Philadelphia. Despite the challenges of losing his mother at a young age, he proved to be an exceptional student.

After graduating from high school at age 16, Frazier enrolled at Pennsylvania State University, where he excelled academically. To help pay for his education, he undertook unusual jobs, including raising tadpoles and newts and selling them to local pet stores.

Frazier graduated from Penn State with a B.A. degree and subsequently enrolled at Harvard Law School, one of the most prestigious legal institutions in the world. He graduated from Harvard with his J.D. in 1978, positioning himself for a career at the highest levels of the legal profession.

Legal career

Drinker Biddle

After graduating from Harvard Law School, Frazier began his legal career at Drinker Biddle & Reath, a prominent Philadelphia law firm. Over the following years, he rose to become a partner at the firm, specializing in litigation.

Death row case

One of the most significant cases of Frazier's legal career came in 1991 when Esther F. Lardent, head of the Death Penalty Representation Project, asked him to defend death row inmate James Willie "Bo" Cochran.

Cochran had been arrested and accused of murdering an assistant manager at a Birmingham, Alabama grocery store in 1976. By the time Frazier took the case, Cochran had spent 15 years on death row.

Frazier, then a partner at Drinker Biddle, assembled a team of colleagues and dedicated years to the case. Their efforts paid off in 1995 when the United States Court of Appeals for the Eleventh Circuit overturned Cochran's conviction. In 1997, Cochran was retried and found not guilty, exonerating a man who had come within days of execution.

Frazier continued to represent Cochran even after leaving Drinker Biddle, demonstrating a commitment to justice that extended beyond professional obligations. The case showcased not only Frazier's legal skills but also his willingness to fight for the underdog—qualities that would later define his corporate leadership.

During his law career, Frazier also took four summer sabbaticals to teach trial advocacy in South Africa during the final years of apartheid, further demonstrating his commitment to justice and equality.

Career at Merck

Joining as general counsel

As a lawyer at Drinker Biddle, one of Frazier's clients was Merck & Co., America's second-largest pharmaceutical company. In 1992, he joined Merck's public affairs division as general counsel, bringing his litigation expertise in-house.

Frazier was named senior general counsel in 1999, positioning him for the greatest challenge of his legal career at Merck.

The Vioxx defense

Frazier's defining legal achievement at Merck was overseeing the company's defense against thousands of lawsuits related to Vioxx, an anti-inflammatory drug that had been linked to heart attacks and strokes.

When the litigation began, analysts estimated Merck's potential liability at between $20 billion and $50 billion—sums that could have bankrupted or severely damaged the company. Frazier later described the Vioxx litigation as "the most significant challenge [he'd] ever faced."

Rather than settling all cases quickly (as many companies facing mass tort litigation do), Frazier chose an aggressive strategy: fighting each case in court. This approach was risky but ultimately successful. The remaining cases were eventually settled in 2007 for $4.85 billion—a substantial sum, but far less than the dire predictions had suggested.

The Vioxx defense demonstrated Frazier's strategic thinking, courage under pressure, and ability to manage extremely complex situations. These qualities caught the attention of Merck's leadership.

Rise to CEO

In 2006, Frazier was promoted to executive vice president while continuing his role as general counsel. He then led the company's largest business unit, Human Health, from 2007 until he was named president of Merck in April 2010.

On January 1, 2011, Frazier became CEO and a member of Merck's board of directors, replacing outgoing CEO Richard Clark. He thus became the first African American to lead a major pharmaceutical company—a breakthrough moment for diversity in corporate America.

Leadership as CEO

As CEO, Frazier directed Merck to take significant financial risks in developing new treatments. In 2013, he made the controversial decision to prioritize research funding over meeting the year's earnings targets—a choice that demonstrated his commitment to long-term value creation over short-term financial metrics.

Frazier placed special emphasis on improving treatments for Alzheimer's disease, a cause with personal resonance: his father had died from Alzheimer's. He also expressed motivation to improve lives in developing countries through access to essential medicines.

Under Frazier's leadership, Merck achieved significant successes including the development of Keytruda, an immunotherapy drug that became one of the best-selling cancer drugs in the world.

Compensation

As CEO of a major pharmaceutical company, Frazier was well compensated:

2014: $21,387,205 total compensation
2015: $17,023,820 total compensation
2016: $21,781,200 total compensation

As of February 2017, Frazier owned 600,304 shares of Merck stock worth approximately $37 million. His pension, accumulated over decades at the company, was valued at $26,593,261 as of December 2016.

Based on stock transactions and his tenure, Frazier's net worth is estimated in the hundreds of millions of dollars.

Stock sales

In July 2016, Frazier sold 60,000 shares of Merck stock at an average price of $64.44.

In 2018, 2019, and 2020, Frazier sold a total of 1,762,490 shares with a combined value at time of sale of $110.23 million.

Retirement as CEO

On February 4, 2021, Merck announced that Frazier would retire as president and CEO at the end of June, transitioning to the role of executive chairman. His tenure had transformed Merck and established a legacy of research investment and ethical leadership.

Public stance on racial issues

Resignation from Trump council

Frazier gained national attention on August 14, 2017, when he became the first CEO to resign from President Donald Trump's American Manufacturing Council following Trump's response to the Unite the Right rally in Charlottesville, Virginia, where white supremacists had rallied and a counter-protester was killed.

In his resignation statement, Frazier objected to Trump's claim that "many sides" were responsible for the violence:

"America's leaders must honor our fundamental views by clearly rejecting expressions of hatred, bigotry and group supremacy, which run counter to the American ideal that all people are created equal."

The resignation was a bold move that placed Frazier in direct opposition to the President of the United States. It drew both praise from those who shared his concerns and criticism from Trump supporters. Other CEOs subsequently followed Frazier's lead, and Trump eventually dissolved the council.

George Floyd statement

On June 1, 2020, in the wake of the murder of George Floyd by Minneapolis police, Frazier gave a powerful interview on CNBC's Squawk Box addressing racial tensions and violence.

In the interview, Frazier spoke movingly about what it meant to be a Black man in America, noting that the situation depicted in Floyd's death "could have been me." The interview was widely viewed and quoted, making Frazier one of the most prominent corporate voices on racial justice.

Stroke initiative

In August 2020, Kenneth Frazier and his wife Andréa donated $5 million to Jefferson Health to work with Temple University on a new stroke initiative specifically targeting African American communities, which face disproportionately high stroke rates.

Other activities

Board memberships

Frazier has served on various corporate and nonprofit boards:

Merck: Executive chairman (current)
ExxonMobil: Director (2009–2022)
Pharmaceutical Research and Manufacturers of America (PhRMA): Board member (2011–2021)
National Constitution Center: Board of directors
Eikon Therapeutics: Board of directors
Cornerstone Christian Academy (Philadelphia): Trustee

Penn State and Sandusky investigation

In November 2011, the Pennsylvania State University board of trustees appointed Frazier, who was himself a trustee, to chair a special committee investigating the Penn State child sex abuse scandal involving former assistant football coach Jerry Sandusky and allegations of a cover-up by university officials.

The investigation relied significantly on the Freeh Report, commissioned by Penn State and conducted by former FBI director Louis Freeh. The report found emails suggesting that university leaders, including head football coach Joe Paterno, had known of reports of Sandusky's abuse but failed to report it.

Frazier faced criticism from Harrisburg attorney William Cluck and Paterno defenders for his handling of the investigation, particularly the reliance on the Freeh Report. At one meeting, when Cluck questioned the report, Frazier delivered a sharp response, comparing skeptics of the report's findings to those who believed in the O.J. Simpson not guilty verdict.

Frazier twice apologized for the outburst, which was characterized as uncharacteristic of his usual measured demeanor.

American Law Institute

Frazier is a member of the American Law Institute and serves on its governing council. In May 2013, he delivered the keynote speech at the ALI Annual Dinner, addressing the intersection of law, business, and ethics.

Recognition

Time 100

Frazier was named to Time magazine's list of the 100 most influential people in the world in both 2018 and 2021, reflecting his impact both within the pharmaceutical industry and in broader American society.

American Philosophical Society

In 2018, Frazier was elected to the American Philosophical Society, America's first learned society founded by Benjamin Franklin in 1743. Membership in the APS is considered one of the highest honors in American intellectual life.

Personal life

Kenneth Frazier is married to Andréa Frazier. The couple has engaged in significant philanthropic activities together, including their $5 million donation for stroke research targeting African American communities.

Frazier's personal connection to Alzheimer's disease—his father died from the disease—has informed his professional focus on neurological conditions and his commitment to research in this area.

Legacy

Kenneth Frazier's legacy encompasses multiple dimensions:

As a barrier-breaker: Frazier was the first African American to lead a major pharmaceutical company, demonstrating that the highest levels of corporate America could be reached by Black executives.

As a legal strategist: His successful defense of Merck in the Vioxx litigation potentially saved the company billions of dollars and established his reputation for handling complex, high-stakes situations.

As a moral voice: His resignation from Trump's Manufacturing Council and his statements on racial justice established him as one of the most prominent corporate voices on ethical issues.

As a pharmaceutical leader: Under his leadership, Merck continued its tradition of research investment and brought important new drugs to market.

As a death penalty opponent: His successful defense of James Willie Cochran demonstrated a commitment to justice that extended beyond corporate interests.

References

External links

Appearances on C-SPAN